Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Risk Adapted De-Intensification of Radio-Chemotherapy for Favorable Prognosis Oropharyngeal Squamous Cell Carcinoma
NCT05268614Phase 2Recruiting
- Sponsor
- University of Florida
- Start
- May 2022
- Primary completion
- Jun 2029
- Modality
- Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of Cisplatin micelle injection (HA132) in oropharyngeal squamous cell carcinoma (OPSCC), sponsored by University of Florida. Started May 2022; status: recruiting.
02
Drugs
Cisplatin micelle injection (HA132)
03
Conditions
oropharyngeal squamous cell carcinoma (OPSCC)
Beyond the preview
Go deeper on NCT05268614.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05268614.